Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as ‘living drugs,’ their toxicity profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Maus, Marcela V, Alexander, Sara, Bishop, Michael R, Brudno, Jennifer N, Callahan, Colleen, Davila, Marco L, Diamonte, Claudia, Dietrich, Jorg, Fitzgerald, Julie C, Frigault, Matthew J, Fry, Terry J, Holter-Chakrabarty, Jennifer L, Komanduri, Krishna V, Lee, Daniel W, Locke, Frederick L, Maude, Shannon L, McCarthy, Philip L, Mead, Elena, Neelapu, Sattva S, Neilan, Tomas G, Santomasso, Bianca D, Shpall, Elizabeth J, Teachey, David T, Turtle, Cameron J, Whitehead, Tom, Grupp, Stephan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745688/
https://www.ncbi.nlm.nih.gov/pubmed/33335028
http://dx.doi.org/10.1136/jitc-2020-001511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745688/
https://www.ncbi.nlm.nih.gov/pubmed/33335028
http://dx.doi.org/10.1136/jitc-2020-001511

Ejemplares similares